Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CVS stock price vs MCK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MCK's multiple
Needs Annual EPS, MCK P/E.
Implied fair value · at CVS's multiple
Needs Annual EPS, CVS P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CVS HEALTH Corp · implied price per share
Reporting currency could not be verified.
MCKESSON CORP · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
CVS · not enough data.
MCK · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Walgreens Boots Alliance, Inc.
CVS vs WBA
UNITEDHEALTH GROUP INC
CVS vs UNH
Walmart Inc.
CVS vs WMT
Cigna Group
CVS vs CI
HUMANA INC
CVS vs HUM
Elevance Health, Inc.
CVS vs ELV
CARDINAL HEALTH INC
CVS vs CAH
AbbVie Inc.
CVS vs ABBV
HENRY SCHEIN INC
CVS vs HSIC
PATTERSON COMPANIES, INC.
CVS vs PDCO
Zoetis Inc.
CVS vs ZTS
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CVS can narrow the earnings gap versus MCK through faster profit growth and lower leverage, then hold or accumulate on weakness because the current P/E premium already prices in a stronger earnings profile than the data currently shows.
CVS's current price of $104.43 is far above MCK-implied price of $31.01, implying 70.3% downside on the P/E framework. The gap is driven mainly by CVS's 75.1x P/E versus MCK's 22.3x, while both names trade at the same 0.3x P/S multiple, suggesting the market is pricing CVS far more aggressively on earnings than on sales.
Supporting Metrics
